Short answer
Steris (STE) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). STERIS announced fiscal second-quarter 2026 results for the quarter ended September 30, 2026.
Steris 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- STERIS announced fiscal second-quarter 2026 results for the quarter ended September 30, 2026
- Detailed financial results and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- Fiscal Q2 revenue $1.6B, up 9%, with 8.1% constant-currency organic growth, indicating broad underlying demand
- Adjusted diluted EPS $2.94, up from $2.47, while GAAP EPS reached $2.19 from $1.94
- Life Sciences strongest segment: revenue up 18% to $170.6M, capital equipment growth 53%, operating income $75.8M
- FY2027 adjusted EPS outlook raised to $11.35-$11.55 from $11.10-$11.30, including $0.18 tariff-refund benefit
- Restructuring adds approximately $45M charges for $9M annualized savings, with full benefits expected in subsequent fiscal years
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Steris 8-K filings
Get the next STE 8-K as it lands
Follow STE for push alerts, or ask the research agent what this filing means.